TrialCell reports. Medicine2023

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

Stefania Capone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.